The latest edition of Springer Nature’s “Behind the Paper” blog series highlights how an interdisciplinary research collaboration involving Jatinder Lamba, Ph.D., M.Sc., associate dean for research and graduate education and the Frank A. Duckworth Eminent Scholar Chair in the University of Florida College of Pharmacy, and Vivek Shastri, Ph.D., a research assistant professor, led to the identification of a rare genomic phenomenon underlying CD33-negative acute myeloid leukemia, or AML.
The Lamba Lab collaborated with a Seattle-based diagnostic laboratory to examine AML cells at the genetic level. Their findings explain why some patients lack CD33 protein expressions — an important distinction that can influence treatment decisions, as these patients are not eligible for CD33-targeted therapies. The blog post accompanies research published April 21 in the journal Leukemia.
(Shastri, V.M., Dai, R., Zhang, Y. et al. Interstitial loss of heterozygosity at Chr19q13 in CD33-negative AML. Leukemia (2026). https://doi.org/10.1038/s41375-026-02963-w“)